Oral Colonisation of the Gut May Explain the Cirrhosis Virome Signature. [PDF]
Liver IntZavos C.
europepmc +1 more source
A Randomized Trial of Rifaximin vs Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome. [PDF]
Clin Gastroenterol HepatolLee AA +20 more
europepmc +1 more source
A systematic stepwise optimization framework for rapid multi-analyte UPLC-MS/MS plasma analysis with integrated sustainability assessment. [PDF]
Sci RepAbd-Elnabi AE +3 more
europepmc +1 more source
Pharmacological targeting of SF3a1-MDM4 splicing vulnerability in ovarian cancer with rifaximin and antisense oligonucleotide. [PDF]
J Transl MedShuai X +5 more
europepmc +1 more source
From dysbiosis to MASLD: The central role of the gut microbiota. [PDF]
Hepatol ForumKhalenkow M, Kaya E, Canbay A.
europepmc +1 more source
Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review. [PDF]
World J MethodolShah Q, Soldera J.
europepmc +1 more source
Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Narrative Review. [PDF]
J Clin Transl HepatolPyrsopoulos NT +3 more
europepmc +1 more source
Proximity-ligation metagenomics reveals differential plasmid and chromosomal antimicrobial resistance gene carriage in disrupted gut ecosystems. [PDF]
iScienceSommer AJ, Auch B, Khoruts A, Bajaj JS.
europepmc +1 more source
Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses. [PDF]
Pharmacol RepPalenca I +4 more
europepmc +1 more source